Atkins, Michael BCuriel-Lewandrowski, ClaraFisher, David ESwetter, Susan MTsao, HensinAguirre-Ghiso, Julio ASoengas, Maria SWeeraratna, Ashani TFlaherty, Keith THerlyn, MeenhardSosman, Jeffrey ATawbi, Hussein APavlick, Anna CCassidy, Pamela BChandra, SunandanaChapman, Paul BDaud, AdilEroglu, ZeynepFerris, Laura KFox, Bernard AGershenwald, Jeffrey EGibney, Geoffrey TGrossman, DouglasHanks, Brent AHanniford, DouglasHernando, EvaJeter, Joanne MJohnson, Douglas BKhleif, Samir NKirkwood, John MLeachman, Sancy AMays, DarrenNelson, Kelly CSondak, Vernon KSullivan, Ryan JMerlino, GlennSoengas, MS2024-10-292024-10-292021-05-15Clin Cancer Res . 2021 May 15;27(10):2678-2697https://hdl.handle.net/20.500.12105/25363The authors are indebted to Dr. Robyn Burns, Science Officer for the Melanoma Research Foundation, for her expert assistance with the preparation of this article. Research reported in this publication was supported, in part, by the NIH SPORE grants (1P50CA221703 to J.E. Gershenwald and P50CA225450 to E. Hernando), DoD/CDMRP Team Science Award (CA170374 to J.E. Gershenwald), the Robert and Lynne Grossman Family Foundation (to J.E. Gershenwald), the Michael and Patricia Booker Melanoma Research Endowment (to J.E. Gershenwald), philanthropic contributions to the Melanoma Moon Shots Program ofMDAnderson (to J.E. Gershenwald), NIH intramural research program (ZIABC008756 to G. Merlino), the InterMEL P01 (P01CA206980 to E. Hernando), and the Melanoma Research Foundation.Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward.engVoRhttp://creativecommons.org/licenses/by/4.0/TARGETED THERAPYSYSTEMIC THERAPYIMMUNOTHERAPYRECOMMENDATIONSASSOCIATIONMORTALITYSUNBURNTUMORAttribution 4.0 International3341413227102678-2697https://pmc.ncbi.nlm.nih.gov/articles/PMC8127340/pdf/nihms-1659932.pdfopen access